Penny stocks are a popular investment choice due to high inflation these days. What are we talking about with penny stocks here? Primarily, because they are easy to invest in and are able to make money quickly. Thanks to Robinhood, retail investors have access to the market. As penny stocks break out, you can see the real retail momentum. If you are interested in getting started, you should check out Robinhood Penny Stock List.
Best Robinhood Stocks To Invest:
Historically, Robinhood may not be the most famous platform for trading penny stocks. However, the broker has flourished owing to its easy-to-use interface, which attracts more investors and traders. In this article, Stocks Telegraph will be discussing the Robinhood penny stocks list for investors who trade through Robinhood.
Waitr Holdings Inc. (WTRH)
The stock of Waitr Holdings Inc. (WTRH) gained 12.25% to complete the last trading session at $0.33. The price range of the company’s shares was between $0.2872 and $0.3538. It traded 16.68 million shares, which was above its daily average of 6.96 million shares over 100 days. WTRH’s shares have gained by 31.83% in the last five days, while they have added 117.84% in the last month. Further, it is currently trading at a price to book ratio of 0.78.
LUXOR CAPITAL GROUP LP bought a fresh place in Waitr Holdings Inc. (NASDAQ: WTRH). The institutional investor bought 127.2 thousand shares of the stock in a transaction took place on 6/29/2022. In another most recent transaction, which held on 6/30/2022, PARKSIDE FINANCIAL BANK & TRUST bought approximately 4.8 thousand shares of Waitr Holdings Inc. In a separate transaction which took place on 6/30/2022, the institutional investor, MONEY CONCEPTS CAPITAL CORP. sold 4.00 shares of the company’s stock. The total Institutional investors and hedge funds own 12.50% of the company’s stock.
Cyclacel Pharmaceuticals Inc. (CYCC)
Cyclacel Pharmaceuticals Inc. (CYCC) stock subtracted -7.69% to finish last trading session at $1.32. The stock recorded a trading volume of 0.85 million shares, which is below the average daily trading volume published for the last 50 days of 0.82 million shares. The shares of Cyclacel Pharmaceuticals Inc. have retreated 8.20% in the last five days; however, they have lost -2.94% over the last one month. The stock price has shed -34.00% over the last three months and has lost -75.74 percent so far this year.
Oppenheimer resumed the [bold-text]Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC)[/bold-text] stock from N/A to Outperform and set the price target of $17. The rating was come out on July 18, 2022. In another research note published on April 27, 2020, by ROTH Capital, resumed the stock to Buy and gave a price target of $24 to CYCC stock. Ladenburg Thalmann initiated the company stock to Buy in a research paper which released on September 07. Analysts at H.C. Wainwright, revealed in a research note on October 16, 2015, said the stock is initiated to Buy and set the price target of $5. In a research paper which was published recently on February 04, 2010, analysts from Roth Capital initiated the Cyclacel Pharmaceuticals Inc. stock to Buy and gave a price target of $7.
Aurora Cannabis Inc. (ACB)
On Friday, shares in Aurora Cannabis Inc. (ACB) fell -7.84% to close the day at $1.41. The volume of shares traded was 7.43 million, which is lower than the average volume over the last three months of 10.81 million. During the trading session, the stock oscillated between $1.38 and $1.5397. The company had an earnings per share ratio of -5.80. ACB’s stock has gained 2.92% of its value in the previous five sessions and 9.30% over the past one month but has lost -73.94% on year-to-date basis. The stock’s 50-day moving average of $1.7570 is above the 200-day moving average of $4.2403. Moreover, the stock is currently trading at RSI of 45.38.
Aurora Cannabis Inc. (ACB) has a 20-day trading average at $1.4240 and the current price is -83.77% off the 52-week high compared with 16.53% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.7570, and its 200-day simple moving average is $4.2403. If we look at the stock’s price movements over the week, volatility stands at 11.83%, which decreases to 10.14% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 45.38 to suggest the stock is neutral.
Momentus Inc. (MNTS)
Momentus Inc. (MNTS) stock lost -5.05% to close Friday’s session at $1.88. The stock volume remained 0.53 million shares, which was lower than the average daily volume of 0.95 million shares within the past 50 days. MNTS shares have fallen by -81.73% over the last 12 months, and they have moved down by -2.08% in the past week. Over the past three months, the stock has lost -39.55%, while over the past six months, it has shed -50.53%. Further, the company has a current market of $150.49 million and its outstanding shares stood at 79.96 million.
Investment analysts at Evercore ISI published a research note on July 05, 2022, where it informed investors and clients that Momentus Inc. (NASDAQ: MNTS) is now rated as Underperform. Their price target on the stock stands at $2. Deutsche Bank also rated MNTS as initiated on January 10, 2022, with its price target of $10 suggesting that MNTS could surge by 81.2% from its current share price. Even though the stock has been trading at $1.98/share, analysts expect it to down by -5.05% to reach $1.88/share.
Protalix BioTherapeutics Inc. (PLX)
Protalix BioTherapeutics Inc. (PLX) stock closed last session at $1.06, decreasing -1.85% or -$0.02. Shares of the company fluctuated between $1.05 and $1.08 throughout the day. The number of shares exchanged was 0.12 million, less than the company’s 50-day daily volume of 0.19 million and lower than its Year-to-date volume of 1.86 million. In the past 12 months, the company’s stock has advanced -36.53%, and in the last one week, the stock has moved down -1.85%. For the last six months, the stock has gained a total of 27.21%, and over the last three months, the stock has decreased by -15.20%. The stock has returned 27.45% so far this year.
Looking at the overall sentiment about this stock we find that the community has adopted a bullish outlook, a sentiment shared by analysts offering their price forecasts for the stock for the next 12 months. 1 analyst have given Protalix BioTherapeutics Inc. (PLX) a consensus price target of $11.00, which is noticeably above its current trading value. The analysts estimate the stock will hit a 12-month high of $11.00, while a downturn for the stock is likely to see it drop to a low of $11.00. When we calculate the distance from the median price, we find that the stock will move 90.36% from its price at the previous close to touch the estimated average price. An upside towards the 12-month high will see the stock climb 90.36%, while a decline to the 12-month low will see the stock lose 90.36 of its current value.